Atezolizumab plus bevacizumab: A novel breakthrough in hepatocellular carcinoma

Florian Castet; Catherine E. Willoughby; Philipp K. Haber; Josep M. Llovet

doi:10.1158/1078-0432.CCR-20-4706

Atezolizumab plus bevacizumab: A novel breakthrough in hepatocellular carcinoma

Florian Castet, Catherine E. Willoughby, Philipp K. Haber, Josep M. Llovet

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

The combination of atezolizumab and bevacizumab increases overall survival compared with sorafenib in advanced hepatocellular carcinoma (HCC). Its approval by the FDAhas launched a newera of combination therapies in advanced and earlier settings that are likely to reshape the management of HCC across all disease stages.

Original language	English
Pages (from-to)	1827-1829
Number of pages	3
Journal	Clinical Cancer Research
Volume	27
Issue number	7
DOIs	https://doi.org/10.1158/1078-0432.CCR-20-4706
State	Published - Apr 2021

Access to Document

10.1158/1078-0432.CCR-20-4706

Cite this

@article{429554ffc3e9450ab83afaca6a8b6a91,

title = "Atezolizumab plus bevacizumab: A novel breakthrough in hepatocellular carcinoma",

abstract = "The combination of atezolizumab and bevacizumab increases overall survival compared with sorafenib in advanced hepatocellular carcinoma (HCC). Its approval by the FDAhas launched a newera of combination therapies in advanced and earlier settings that are likely to reshape the management of HCC across all disease stages.",

author = "Florian Castet and Willoughby, {Catherine E.} and Haber, {Philipp K.} and Llovet, {Josep M.}",

note = "Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",

year = "2021",

month = apr,

doi = "10.1158/1078-0432.CCR-20-4706",

language = "English",

volume = "27",

pages = "1827--1829",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

TY - JOUR

T1 - Atezolizumab plus bevacizumab

T2 - A novel breakthrough in hepatocellular carcinoma

AU - Castet, Florian

AU - Willoughby, Catherine E.

AU - Haber, Philipp K.

AU - Llovet, Josep M.

PY - 2021/4

Y1 - 2021/4

N2 - The combination of atezolizumab and bevacizumab increases overall survival compared with sorafenib in advanced hepatocellular carcinoma (HCC). Its approval by the FDAhas launched a newera of combination therapies in advanced and earlier settings that are likely to reshape the management of HCC across all disease stages.

AB - The combination of atezolizumab and bevacizumab increases overall survival compared with sorafenib in advanced hepatocellular carcinoma (HCC). Its approval by the FDAhas launched a newera of combination therapies in advanced and earlier settings that are likely to reshape the management of HCC across all disease stages.

UR - http://www.scopus.com/inward/record.url?scp=85104861616&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-20-4706

DO - 10.1158/1078-0432.CCR-20-4706

M3 - Article

C2 - 33472912

AN - SCOPUS:85104861616

SN - 1078-0432

VL - 27

SP - 1827

EP - 1829

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 7

ER -

Atezolizumab plus bevacizumab: A novel breakthrough in hepatocellular carcinoma

Abstract

Access to Document

Fingerprint

Cite this